BLR&D Research Career Scientist Award Application

前列腺癌、肾癌和膀胱癌(泌尿系恶性肿瘤)是最常见的。 我们退伍军人的死因。因此，有一种迫切的未得到满足的需求 这些恶性肿瘤的治疗。为了解决这些问题，申请人一直在 自1987年以来，泌尿系恶性肿瘤领域。申请者的主要目标有三个 研究：1)探讨肿瘤发生、发展和转移的分子机制 泌尿系恶性肿瘤。2)寻找诊断和判断预后的分子生物学标志物。 泌尿系癌症。3)使用天然化合物治疗泌尿系癌症。要完成 为了实现这些目标，申请者已经收到了退伍军人管理局和美国国立卫生研究院资助的几个项目 退伍军人协会和非退伍军人协会的临床医生和科学家。 申请者卓有成效地发表了350篇同行评议的科学出版物。 他在退伍军人管理局拥有27年的卓越职业生涯。在他的职业生涯中， 他一直站在泌尿系癌症分子机制研究的前沿。他的 研究工作得到了几个NIH/VA资助的项目的支持，目前，他有一个VA荣誉 审查奖和两个NIH资助的RO1项目。他已经培训了50多名研究员和大多数 他们中的许多人都是有资助研究项目的机构的教职员工。 申请人与退伍军人管理局调查人员和非退伍军人管理局调查人员广泛合作 在资助的项目和科学出版物中。这位申请人是第一个收到 美国国务院前列腺癌研究促进奖计划 退伍军人事务部(PI：Dahiya，1999-2012年)。他已经培训了几位科学家，与 退伍军人事务部临床医生科学家。 最近，申请者收到了一个关于遗传生物标记物的作用的退伍军人管理局项目 前列腺癌的临床评估“(PIs：Dahiya，Tanaka，Lau，10-2012-09-2017) 与四名退伍军人事务部科学家和临床医生合作。在这个项目下，他的团队已经调查了 SNPs、CpG甲基化、miRNAs和X连锁基因是否可以共同预测 局限性前列腺癌患者发生转移的风险更高，因此需要 更积极的干预。 目前，申请人已获得退伍军人事务部荣誉评审奖c-Myc/HIF途径调控奖 在肾癌的管理方面“(PI：Dahiya，10/2011-09/2020)和两个NIH RO1项目 UO1CA184966“种族相关前列腺癌的遗传因素”(PI：Dahiya 07/2015-06/2020) 和RO1CA199694《使用非编码RNA预测肾癌预后的分子生物标记物》 (PI：Dahiya 06/2016-05/2021) 总之，申请者的科学贡献对退伍军人管理局的任务至关重要。 他在泌尿系癌症领域取得了突破性的发现，并提供了 为科学界和退伍军人制度提供大量资源。申请人的实验室 在表观遗传学领域做出了几项重大贡献(DNA甲基化、组蛋白 修饰，染色质重塑)，非编码RNA(dsRNA，miRNAs)，各种SNPs 基因及其在诊断、预后、进展、转移和风险评估中的作用 泌尿系恶性肿瘤的治疗。这些是我们退伍军人管理局医疗保健的高度优先计划 系统。

Prostate, kidney and bladder cancers (urological malignancies) are the most common cause of death among our Veterans. Therefore, there is an urgent unmet need for the management of these malignancies. To address these issues, the applicant has been working in the field of urological malignancies since 1987. There are three main goals of the applicant's research: 1) To investigate the molecular mechanisms of initiation, progression and metastasis of urological malignancies. 2) To identify molecular biomarkers for diagnosis and prognosis of urological cancers. 3) Treatment of urological cancers using natural compounds. To accomplish these goals, the applicant has received several VA and NIH funded projects in collaboration with VA and Non-VA clinicians and scientists. The applicant has been very productive with 350 scientific publications in peer-reviewed journals and has had a distinguished career for 27 years in the VA system. Throughout his career, he has been at the forefront of research into the molecular mechanisms of urological cancers. His research work is supported by several NIH/VA funded projects and currently, he has one VA Merit Review award and two NIH funded RO1 projects. He has trained more than 50 fellows and most of them are faculty members at various institutions with funded research programs. The applicant has extensively collaborated with VA investigators and non-VA investigators in funded program projects and scientific publications. The applicant was the first one to receive a REAP (Research Enhancement Award Program) on prostate cancer from the Department of Veterans Affairs (PI: Dahiya, 1999-2012). He has trained several scientists in collaboration with VA clinician scientists. Recently, the applicant received a VA program project on the “Role of genetic biomarkers in clinical assessment of prostate cancer” (PIs: Dahiya, Tanaka, Lau, 10-2012-09-2017) in collaboration with four VA scientists and clinicians. Under this program, his team has investigated whether SNPs, CpG methylation, miRNAs and X-linked genes together can predict which localized prostate cancer patients have a higher risk of developing metastasis and thus require more aggressive interventions. Currently, the applicant has a VA Merit Review award “ Regulation of c-Myc/HIF pathway in the management of kidney cancer” (PI: Dahiya, 10/2011-09/2020) and two NIH RO1 projects UO1CA184966 “Genetic factors for race related prostate cancer” (PI: Dahiya 07/2015-06/2020) and RO1CA199694 “Molecular biomarkers for kidney cancer prognosis using non-coding RNAs (PI: Dahiya 06/2016-05/2021) In summary, the applicant's scientific contributions are vitally important to the VA mission. He has made ground breaking discoveries in the field of urological cancers and has also provided significant resources to the scientific community and the VA system. The applicant's laboratory has made several significant contributions to the fields of epigenetics (DNA methylation, histone modification, chromatin remodeling), non-coding RNAs (dsRNA, miRNAs), SNPs of various genes and their roles in diagnosis, prognosis, progression, metastasis and risk assessment and treatment of urological malignancies. These are high priority programs for our VA health care system.